卢拉西治疗双极性抑郁症的有效性和可接受性:系统性审查和剂量反应元分析
Yu-Wei Lin1, Yang-Chieh Brian Chen1, Kuo-Chuan Hung2
1Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
BMJ mental health
|November 18, 2024
概括
每天服用40-60毫克的卢拉西有效治疗双极性抑郁症,改善情绪和焦虑症状. 虽然更高的剂量会增加副作用,但这种范围提供了一个平衡的治疗选择.
科学领域:
- 精神病学是一种精神病学.
- 药理学 药理学是指药理学的学科.
- 临床神经科学 临床神经科学
背景情况:
- 对于治疗双极性抑郁症而言,卢拉西的最佳剂量仍然不确定.
- 这项研究系统地评估了卢拉西的剂量反应关系.
研究的目的:
- 为了确定对双极性抑郁症有效性的卢拉西的最佳剂量.
- 评估不同剂量的卢拉西的可接受性和代谢/内分泌影响.
主要方法:
- 在2024年8月之前对五个数据库和灰色文献进行系统审查.
- 随机临床试验的元分析 (N=2032) 评估疗效,可接受性和代谢概况.
- 结果包括抑郁症得分,焦虑,总体印象,残疾,生活质量,学率,副作用和代谢/内分泌变化.
主要成果:
- 40-60毫克的卢拉西剂量在抑郁症,焦虑症和临床总体印象方面显著改善.
- 副作用随着更高的卢拉西剂量 (50-100毫克) 增加,但脱学,躁狂转变和自杀倾向没有显示出剂量影响关系.
- 在剂量低于60毫克时观察到体重增加,而高剂量 (例如100毫克) 时血糖和益生菌度增加.
结论:
- 建议每天服用40-60毫克的卢拉西剂量用于治疗双极性抑郁症.
- 这种剂量范围在有效性和耐受性之间提供了有利的平衡.
- 进一步的研究可能会探索基于代谢概况的个性化剂量策略.
相关概念视频
01:24Mania and Antimanic Drugs: Overview
136
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
136
01:23Antidepressant Drugs: MAOIs and Other Agents
195
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
195
01:26Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104
01:21Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
01:28Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147